Home

The Global Biotech Industry Comes to BIO

  • Recommend
  • Tweet
  • Print
  • Email

South Korea:  Attendees at the BIO International Convention will have the opportunity to listen to an International Case Study on South Korea. The panel will explore the opportunity of cross-border deal making in Korea as leading pharmaceutical and biotechnology companies continue to globalize their R & D and commercial organizations. Attendees can expect to explore new transactional opportunities in the Korean biotechnology market and discuss strategy options for emerging market development in Asia.

Spain:  Spain’s biotechnology sector has recently experienced significant growth averaging 60 new companies per year, with numerous companies entering in later development stages. In the healthcare area, Spain is a leading country in oncology, neurodegenerative diseases, vaccines and other advanced therapies. Each year, 12,000 patients receive treatment with biotech medicines and 400,000 vaccine doses are delivered. More than 75% of the people in the Spanish population think that biotechnology is beneficial. Besides, we rank as the first European country in genetically modified organisms (GMOs) cropping, specifically, of corn, and as one of the most advanced countries regarding the generation of biofuels and energy generation by way of biomass.

UK:  The UK offers one of the biggest country presences at Convention and provides a number of exciting opportunities for companies wanting to grow their business within the UK or source a UK-based partner. The Life Sciences are an important growth area and can also help the UK meet societal challenges such as improving healthcare, improving sustainability and decarbonising the economy. The use of biotechnology is expanding across the economy. Biotechnology is now being used in industrial applications and will help to reduce the UK’s dependence on non–renewable feedstock for producing a wide variety of products from tyres to plastics. UK companies are utilising biotechnology to develop improvements that could lead to new drugs and improved feedstock for industry.

* Source of content:  International Delegations

Access all of the Country Profiles.

Please note that  International Case Studies   are open to attendees with Convention Access, Education Access and Exhibitors.